Micro-Partnerships With Academia Helping To Drive Bristol’s Pipeline Development
New agreement with Duke Translational Medicine Institute highlights Bristol-Myers Squibb’s particular approach to collaborating with academia – small, low-money partnerships that get pharma and university scientists working together in an atmosphere virtually free of corporate bureaucracy.
You may also be interested in...
Bristol-Myers Squibb forms an alliance with Emory University to conduct mid- and late-stage trials in oncology, metabolics, hepatitis C, and immunoscience using BMS compounds.
Inspired by the correlative research during the clinical trials for Yervoy, BMS teams up with ten institutions from across the globe to find biomarkers in post-response data.
Merck announced March 15 that it plans to invest $90 million over the next seven years in a nonprofit biomedical research center in San Diego dubbed the California Institute for Biomedical Research, or Calibr.